Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
Newly reported data to be presented in the oral presentation will include pooled results, as well as individual results, of the Phase 3 studies with SB204 in changes in inflammatory, non-inflammatory and total lesion counts and the proportion of patients achieving success on the Investigator Global Assessment, or IGA. Additionally, the presentation will include safety and efficacy results of the 40-week long term open label trial with SB204.
“The pooled efficacy data from the two Phase 3 trials, combined with a sustained treatment benefit over an additional 40 weeks in the long-term safety trial and favorable safety profile, further demonstrate the potential of nitric oxide and its multiple mechanisms of action as a promising treatment for acne,” stated Dr. Hebert. “I am most intrigued by the improvement observed in the severely diseased population treated with SB204. Patients with severe acne have limited treatment options that are safe and accessible, and are in need of well-tolerated topical alternatives.”
About the Presentation
Abstract Number: 6705
Title: “Evaluation of the Efficacy, Safety, and Tolerability of SB204 4%
Authors: A. Hebert,
Date and Time:
Acne vulgaris is the most common skin condition in the U.S., affecting approximately 40 million to 50 million Americans annually. The disease ranges in severity from mild to severe cystic acne and causes both physical and psychological effects, including permanent scarring, anxiety, depression and poor self-esteem. The complexity of the disease requires treatments that address more than one of the major causes of acne pathogenesis.
This press release contains forward-looking statements including, but not limited to, statements related to our operations and business strategy. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, risks and uncertainties related to our interpretation of data from preclinical studies or clinical trials and other risks and uncertainties described in our annual report filed with the
Director, Corporate Communications and Administration